Clinical Trial Update: Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial [Phase 2]

View source ↗

Summary

A single-arm Phase 2 clinical trial evaluating transarterial infusion of a PD-1 antibody combined with TACE-HAIC for unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)
• TACE-HAIC

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN